DHC vs VTR: Which Is the Better Buy in 2026?
Last updated September 2026
Short answer
VTR is the larger of the two ($47.23B market cap): the incumbent the market prices for continued execution (100.62x forward earnings, beta 0.73). DHC is the smaller challenger ($1.85B), priced similarly on forward earnings (-17.54x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
DHC vs VTR: the tie-breaker metrics
Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | DHC | VTR | What it tells you |
|---|---|---|---|
| Market cap | $1.85B | $47.23B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -17.54 | 100.62 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 2.31 | 0.73 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 66% of range | 73% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.17 | 3.22 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how DHC and VTR affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DHC and VTR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DHC and VTR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Diversified Healthcare Trust (DHC) do?
Diversified Healthcare Trust is a real estate investment trust that owns a roughly $6.2 billion portfolio of about 285 properties across 33 states and Washington, D.C. Its assets split into two main buckets: a senior housing operating portfolio (SHOP, roughly 23,900 senior living units) and medical office plus life science space (about 5.6 million square feet leased to roughly 250 tenants). DHC is externally managed by The RMR Group (Nasdaq: RMR), a commercial real estate asset manager with over $37 billion under management, so DHC has no employees of its own and pays management fees to RMR.
What does Ventas (VTR) do?
Ventas, Inc. is an S&P 500 healthcare real estate investment trust that owns roughly 1,400 properties across North America and the United Kingdom, spanning senior housing communities, outpatient medical buildings, and research and lab (life science) assets. Its defining shift has been toward its senior housing operating portfolio (SHOP), which now accounts for more than half of net operating income and gives Ventas direct exposure to occupancy, rate, and margin trends rather than just fixed lease income. The company owns over 850 senior housing communities, and management has leaned hard into buying them, raising 2026 investment guidance to about $3 billion because acquiring communities has looked more attractive than building.
DHC vs VTR: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- DHC drivers: Senior housing (SHOP) recovery; Deleveraging and maturity runway.
- VTR drivers: Senior housing (SHOP) demographic tailwind; Capital deployment into acquisitions.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: DHC is a leveraged small-cap REIT and remains higher risk than large diversified peers. For VTR, as an operating (SHOP-heavy) REIT, Ventas carries more earnings variability than a pure net-lease landlord because occupancy, labor costs, and rate growth flow straight to NOI.
DHC or VTR: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DHC if you believe its drivers more; VTR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DHC and VTR guides.
DHC vs VTR: the full fundamentals
DHC. DHC is a small-cap REIT best measured on FFO and NOI rather than net income, since large non-cash items (depreciation, impairments, gains on sales) swing reported earnings. On a price-to-normalized-FFO basis (~$0.52-0.58 for 2026 against a high-single-digit share price) it screens cheap versus larger healthcare REITs, reflecting its leverage and recovery risk. The near-zero common dividend means valuation rests on the balance sheet and NOI trajectory, not yield.
VTR. VTR trades around $96 with a market cap near $47 billion, making it the second-largest healthcare REIT behind Welltower. At roughly a mid-20s price-to-FFO multiple, the market is paying up for a fifth consecutive year of double-digit senior housing NOI growth. The dividend yield is modest for a REIT at about 2.1%, reflecting both the growth premium and a payout that management has been rebuilding since the pandemic.
Headline figures (approximate, July 2026): DHC shows revenue (q1 2026) ~$366.5M, revenue (ttm) ~$1.45B, net loss (q1 2026) ~$43.3M (-$0.18/sh), normalized ffo (2026 guide) ~$125-140M ($0.52-0.58/sh); VTR shows revenue (ttm) ~$5.7B, q1 2026 revenue ~$1.66B, normalized ffo/share (q1 2026) ~$0.94, 2026 ffo/share guidance ~$3.82-$3.89.
The bottom line: DHC vs VTR
DHC and VTR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DHC and VTR exposure against your real portfolio. It is not an investment adviser.
Wondering how DHC or VTR fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Diversified Healthcare Trust with AI
Connect the broker you already use and ask Walnut's AI how DHC fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between DHC and VTR?
+
Diversified Healthcare Trust is a real estate investment trust that owns a roughly $6.2 billion portfolio of about 285 properties across 33 states and Washington, D.C. Ventas, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is DHC or VTR the better stock?
+
Neither is universally better. VTR is the larger incumbent; DHC is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, DHC or VTR?
+
On forward P/E (as of September 2026), DHC trades at -17.54x and VTR at 100.62x, so DHC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both DHC and VTR?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of DHC vs VTR?
+
DHC: DHC is a leveraged small-cap REIT and remains higher risk than large diversified peers. It still posts net losses (a ~$43.3 million loss in the first quarter of 2026), carries roughly $2.4 billion of debt against a ~$2.2 billion equity market cap, and pays only a token $0.01 quarterly common dividend, so it is not an income vehicle. As an externally managed REIT, it pays fees to The RMR Group, which can create conflicts of interest that some investors dislike. The senior housing recovery could stall on labor costs, occupancy softness, or higher-for-longer interest rates, and asset sales could dilute future earnings if made at weak prices. The stock is volatile and sensitive to interest rate moves. VTR: As an operating (SHOP-heavy) REIT, Ventas carries more earnings variability than a pure net-lease landlord because occupancy, labor costs, and rate growth flow straight to NOI. A premium FFO multiple (roughly mid-20s price-to-FFO) leaves little room for disappointment if senior housing growth decelerates or supply eventually catches up. Interest rates matter twice: higher rates raise the cost of the debt REITs rely on and can pressure REIT valuations broadly. Large ongoing acquisitions carry integration and pricing risk, and any renewed pressure on senior housing occupancy (from a health event or weaker demand) would hit results directly. Life science and outpatient medical demand can also soften with tenant budgets.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DHC or VTR; figures are approximate and dated (as of September 2026). Verify current data before investing.